Janssen Sciences Ireland Uc

🇮🇪Ireland

Country: 🇮🇪Ireland

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection

Phase 2

Completed

Conditions: Hepatitis B

Interventions: Drug: JNJ-56136379
Drug: Placebo
Drug: NA (ETV or TDF)

First Posted Date: 2017-12-05

Last Posted Date: 2022-11-17

Lead Sponsor: Janssen Sciences Ireland UC

Target Recruit Count: 232

Registration Number: NCT03361956

Locations: 🇭🇰
Queen Mary Hospital, University of Hong Kong, Hong Kong, Hong Kong
🇯🇵
Musashino Red Cross Hospital, Musashino, Japan
🇧🇪
Cliniques Universitaires Saint-Luc, Bruxelles, Belgium

and more 73 locations

A Study in Healthy Female Participants to Investigate the Effect of JNJ-56136379 at Steady-state on the Single-dose Pharmacokinetics of Ethinylestradiol and Drospirenone (Oral Contraceptive) and on the Single-dose Pharmacokinetics of Midazolam (Probe Substrate for Cytochrome P450 3A4)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Drospirenone/Ethinylestradiol
Drug: Midazolam
Drug: JNJ-56136379

First Posted Date: 2017-04-12

Last Posted Date: 2017-09-06

Lead Sponsor: Janssen Sciences Ireland UC

Target Recruit Count: 18

Registration Number: NCT03111511

Locations: 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium

A Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Participants (Part I), and After Multiple Dose Regimens in Participants With Chronic Hepatitis B (Part II)

Phase 1

Completed

Conditions: Healthy
Hepatitis, Chronic

Interventions: Drug: JNJ-56136379
Drug: Placebo

First Posted Date: 2016-01-25

Last Posted Date: 2019-07-05

Lead Sponsor: Janssen Sciences Ireland UC

Target Recruit Count: 87

Registration Number: NCT02662712

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection

Phase 1

Terminated

Conditions: Virus Diseases
Respiratory Syncytial Virus Infections

Interventions: Drug: JNJ-53718678
Drug: Placebo

First Posted Date: 2015-11-01

Last Posted Date: 2019-12-06

Lead Sponsor: Janssen Sciences Ireland UC

Target Recruit Count: 45

Registration Number: NCT02593851

A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide fixed-dose combination (FDC)
Drug: Emtricitabine/tenofovir alafenamide FDC
Drug: Darunavir
Drug: Cobicistat

First Posted Date: 2015-10-19

Last Posted Date: 2017-04-04

Lead Sponsor: Janssen Sciences Ireland UC

Target Recruit Count: 126

Registration Number: NCT02578550

Relative Bioavailability of Three Oral Formulations Candidates of Rilpivirine for Potential Pediatric Use Compared to Oral Tablet

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Rilpivirine Oral Tablet
Drug: Rilpivirine formulation G007
Drug: Rilpivirine formulation G009-01
Drug: Rilpivirine formulation G002
Dietary Supplement: Standardized Breakfast

First Posted Date: 2015-09-28

Last Posted Date: 2016-06-10

Lead Sponsor: Janssen Sciences Ireland UC

Target Recruit Count: 32

Registration Number: NCT02561936

A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies

Phase 2

Active, not recruiting

Conditions: Human Immunodeficiency Virus Type 1

Interventions: Drug: Rilpivirine

First Posted Date: 2015-07-13

Last Posted Date: 2024-12-10

Lead Sponsor: Janssen Sciences Ireland UC

Target Recruit Count: 48

Registration Number: NCT02494986

Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide FDC
Drug: Elvitegravir /Cobicistat/Emtricitabine/Tenofovir alafenamide FDC
Other: High-fat Breakfast
Drug: Darunavir
Drug: Emtricitabine/Tenofovir alafenamide (FTC/TAF)
Drug: Cobicistat
Other: Standardized Regular Breakfast

First Posted Date: 2015-06-18

Last Posted Date: 2017-10-17

Lead Sponsor: Janssen Sciences Ireland UC

Target Recruit Count: 72

Registration Number: NCT02475135

A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects

Phase 3

Completed

Conditions: Immunodeficiency Virus Type 1, Human

Interventions: Drug: DRV/COBI FDC
Drug: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC
Drug: FTC/TDF FDC
Drug: FTC/TDF FDC Matching Placebo
Drug: DRV/COBI FDC Matching Placebo
Drug: D/C/F/TAF FDC - Matching Placebo

First Posted Date: 2015-04-30

Last Posted Date: 2022-09-28

Lead Sponsor: Janssen Sciences Ireland UC

Target Recruit Count: 725

Registration Number: NCT02431247

Study to Evaluate Taste Profile of Different JNJ-53718678 Oral Liquid Formulations in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Formulation A
Drug: Formulation M1
Drug: Formulation B
Drug: Formulation M2
Drug: Formulation C
Drug: Formulation M3
Drug: Formulation D
Drug: Formulation N1
Drug: Formulation E
Drug: Formulation N2
Drug: Formulation F
Drug: Formulation N3

First Posted Date: 2015-04-27

Last Posted Date: 2018-05-15

Lead Sponsor: Janssen Sciences Ireland UC

Target Recruit Count: 12

Registration Number: NCT02426632

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy